Trials / Completed
CompletedNCT00421590
Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide).
A Randomized, Partially Blind, Placebo Controlled, Crossover, Single Oral Dose Study to Assess the Effect of Concomitant Antacid (Calcium Carbonate / Magnesium Hydroxide) on the Pharmacokinetics and Pharmacodynamics of SMC021 (0.8 mg Salmon Calcitonin/200 mg 5-CNAC) in Healthy Postmenopausal Women
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (planned)
- Sponsor
- Novartis · Industry
- Sex
- Female
- Age
- 40 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the effect of concomitant antacid on the pharmacokinetics and pharmacodynamics of SMC021
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SMC021 |
Timeline
- Start date
- 2006-10-01
- First posted
- 2007-01-12
- Last updated
- 2007-06-22
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT00421590. Inclusion in this directory is not an endorsement.